- Product Name: Ad-p53; Ad5CMV-p53 Gene
- Vaccine Ontology ID: VO_0007594
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: p53
- human TP53 (P53)
gene engineering:
- Type: Recombinant protein preparation
- Detailed Gene Information: Click Here.
- Description: A replication-defective adenoviral-CMV vector that encodes a wild-type p53 gene. Ad5CMV-p53 induces tumor cells that have been transfected with the vector to produce wild-type p53, a tumor suppressor gene that is deleted or mutated in a significant number of cancers. In transfected tumor cells, the wild-type p-53 gene product exerts an antitumor effect by blocking cell cycle progression at the G1/S regulation point, activating DNA repair proteins in the presence of DNA damage, and initiating apoptosis when DNA damage is irreparable. (NCI04) (NCIT_C2471).
|
- Vaccine Ontology ID: VO_0007619
- Type: Dendritic cell
- Status: Clinical trial
- Preparation: The vaccine (IDD-3) consisted 8 doses of autologous monocyte-derived matured DC generated in serum-free medium with granulocyte macrophage colony stimulating factor (GM-CSF) and interleukin-13 (IL-13), pulsed with lysates of three allogeneic melanoma cell lines, and matured with interferon gamma (Ribas et al., 2010).
- Immunization Route: Intramuscular injection (i.m.)
- Description: The administration of matured DC loaded with tumor lysates has significant immunogenicity and antitumor activity in patients with limited metastatic melanoma (Ribas et al., 2010).
|
